About Pathalys
Pathalys is a company based in Raleigh (United States) founded in 2021. Pathalys has raised $105 million across 2 funding rounds from investors including J P Morgan, The Carlyle Group and Marshall Wace. Pathalys offers products and services including Upacicalcet. Pathalys operates in a competitive market with competitors including Evergreen Nephrology, AdaptX, Bial, Specialty Networks and Ceresti, among others.
- Headquarter Raleigh, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pathalys Pharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$105 M (USD)
in 2 rounds
-
Latest Funding Round
$105 M (USD), Series B
Aug 20, 2024
-
Investors
J P Morgan
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pathalys
Pathalys offers a comprehensive portfolio of products and services, including Upacicalcet.
Treats secondary hyperparathyroidism in kidney disease patients.
Funding Insights of Pathalys
Pathalys has successfully raised a total of $105M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $105 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pathalys
Pathalys has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, The Carlyle Group and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked | |
|
Long-short equity strategies are managed through specialized hedge funds.
|
Locked | Locked | Locked |
Investor details for Pathalys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pathalys
Investment portfolio details for Pathalys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pathalys
Detailed financials for Pathalys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pathalys Comparisons
Peer comparison for Pathalys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pathalys
Pathalys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evergreen Nephrology, AdaptX, Bial, Specialty Networks and Ceresti, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Chronic care management services for kidney diseases are provided.
|
|
| Locked | Locked | Locked |
Clinical management solutions are provided for healthcare by AdaptX.
|
|
| Locked | Locked | Locked |
Develops and commercializes pharmaceutical products through research and global distribution.
|
|
| Locked | Locked | Locked |
Specialty Networks is focused on supporting independent specialty healthcare providers.
|
|
| Locked | Locked | Locked |
Provider of chronic care management and monitoring solutions
|
Detailed competitors of Pathalys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pathalys
Complete news archive for Pathalys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pathalys
Pathalys was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Pathalys is headquartered in Raleigh, United States. It is registered at Raleigh, North Carolina, United States.
Neal Fowler is the current CEO of Pathalys.
Pathalys is a funded company, having raised a total of $105M across 2 funding rounds to date.
Pathalys was founded in 2021 and is based in Raleigh, United States. Development services for biotherapeutics targeting chronic kidney disease are provided within the biotechnology sector. Operations center on advancing therapeutic solutions for CKD patients. The company is led by CEO Neal Fowler, with a focus on research and innovation in renal health treatments.
Pathalys's top competitors include Evergreen Nephrology, Aqtual and AdaptX.
Pathalys offers Upacicalcet.
Pathalys has 11 investors. Key investors include J P Morgan, The Carlyle Group, Marshall Wace, Orbimed, and Abingworth.